Sonesitatug vedotin

Phase 3Antibody–drug conjugate

Sonesitatug vedotin is one of 67 small molecule programs targeting Esophageal Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal AdenocarcinomaActive, not recruiting

Gastric CancerRecruiting

Stomach NeoplasmsRecruiting

Esophageal AdenocarcinomaPhase 3

Active, not recruiting

Gastric CancerPhase 3

Recruiting

Stomach NeoplasmsPhase 2

Recruiting

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Elunate

Takeda

Phase 3

6 2

CAR T Cells

CChongqing Precision Biotech Co., Ltd

Phase 3

1 3

Sonesitatug vedotin

AstraZeneca

Phase 3

1 4

Gemzar

Johnson & Johnson

Preclinical

—5

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 6

S1,

CChinese Academy of Medical Sciences

Preclinical

17 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 8

Glutamine

Sanofi

Preclinical

1 9

Induction Phase1

Genmab

Preclinical

1 10

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Stomach Neoplasms

NCT06630130

Q4 2031

Phase 3Recruiting

Gastric Cancer

NCT07431281

Clinical

Trials by Indication[1]

Stomach Neoplasms1 trial

A Phase II Platform Trial of Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer (Neo-VIKTORY)

Recruiting·JJeeyun Lee·Phase 2·NCT06630130·100 enrolled

Gastric Cancer1 trial

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07431281·2,130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Sonesitatug vedotin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sonesitatug vedotin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sonesitatug vedotin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Sonesitatug vedotin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q4 2031

Trials by Indication[1]

Stomach Neoplasms1 trial

Gastric Cancer1 trial

References

Drug Info

Quick Facts

Related News